$19.15
1.32% yesterday
NYSE, Dec 12, 10:06 pm CET
ISIN
US0718131099
Symbol
BAX

Baxter International Stock price

$19.15
+0.45 2.41% 1M
-12.21 38.93% 6M
-10.01 34.33% YTD
-11.69 37.91% 1Y
-33.48 63.61% 3Y
-59.68 75.71% 5Y
-17.38 47.58% 10Y
-1.80 8.58% 20Y
NYSE, Closing price Fri, Dec 12 2025
+0.25 1.32%

New AI Insights on Baxter International Insights AI Insights on Baxter International

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$9.8b
Enterprise Value
$17.6b
Net debt
$7.8b
Cash
$1.7b
Shares outstanding
514.0m
Valuation (TTM | estimate)
P/E
negative | 8.0
P/S
0.9 | 0.9
EV/Sales
1.6 | 1.6
EV/FCF
72.2
P/B
1.4
Dividends
DPS
$0.52
Yield 1Y | 5Y
2.7% | 2.0%
Growth 1Y | 5Y
-50.0% | -11.5%
Payout 1Y | 3Y
-81.9% | -380.7%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$11.0b | $11.2b
EBITDA
$1.0b | $2.5b
EBIT
$702.0m | $1.6b
Net Income
$-341.0m | $1.2b
Free Cash Flow
$244.0m
Growth (TTM | estimate)
Revenue
-21.2% | 5.2%
EBITDA
-34.4% | 125.8%
EBIT
56.3% | 85.4%
Net Income
-415.7% | 288.9%
Free Cash Flow
-56.3%
Margin (TTM | estimate)
Gross
35.0%
EBITDA
9.1% | 22.0%
EBIT
6.4%
Net
-3.1% | 11.0%
Free Cash Flow
2.2%
Financial Health
Equity Ratio
27.0%
Return on Equity
-9.3%
ROCE
4.1%
ROIC
5.0%
Debt/Equity
1.3
More
EPS
$-0.7
FCF per Share
$0.5
Short interest
9.7%
Employees
38k
Rev per Employee
$280.0k
Show more

Is Baxter International a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Baxter International Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Baxter International forecast:

2x Buy
8%
16x Hold
64%
7x Sell
28%

Analyst Opinions

25 Analysts have issued a Baxter International forecast:

Buy
8%
Hold
64%
Sell
28%

Financial data from Baxter International

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
11,023 11,023
21% 21%
100%
- Direct Costs 7,161 7,161
17% 17%
65%
3,862 3,862
28% 28%
35%
- Selling and Administrative Expenses 2,435 2,435
27% 27%
22%
- Research and Development Expense 569 569
11% 11%
5%
1,001 1,001
34% 34%
9%
- Depreciation and Amortization 299 299
72% 72%
3%
EBIT (Operating Income) EBIT 702 702
56% 56%
6%
Net Profit -341 -341
416% 416%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Baxter International directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Baxter International Stock News

Neutral
GlobeNewsWire
about 8 hours ago
The complaint alleges Baxter hid serious Novum LVP defects and injuries, gave inadequate fixes, and misled investors about safety and sales prospects.
Neutral
Business Wire
about 23 hours ago
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX) securities between February 23, 2022 and October 29, 2025, inclusive (the “Class Per...
Neutral
GlobeNewsWire
one day ago
LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Dr. Walter Jacobson, a Los Angeles-based psychiatrist, author, and first-time filmmaker, scored a major win at this year's American Film Market (AFM) Pitch Conference when his outrageous comedy, Baxter's Brain, took 3rd place from a panel of industry judges, including award-winning producer Cassian Elwes, screenwriting professor and coach Lee Jessu...
More Baxter International News

Company Profile

Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Head office United States
CEO D. Shafer
Employees 38,000
Founded 1931
Website www.baxter.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today